MedTrace Logo

IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes

NCT06559488 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-08-27

No results posted yet for this study

Summary

Recurrent vitreous hemorrhage following pars plana vitrectomy (PPV) for proliferative diabetic retinopathy remains a significant complication with reported incidence ranging from 11 to 75%. Early and late recurrences are associated with various factors, including residual blood, fibrovascular tissue, and neovascularization. Despite attempts to reduce this complication with therapies like anti-fibrinolytic agents, gas tamponade, and peripheral cryotherapy, the outcomes remain unsatisfactory.

Conditions

Interventions

DRUG

Bevacizumab Injection [Avastin]

Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.

PROCEDURE

Pars Plana Vitrectomy

routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients

Sponsors & Collaborators

  • Cicendo Eye Hospital

    collaborator UNKNOWN

  • Universitas Padjadjaran

    lead OTHER

Principal Investigators

  • Mohamad Eko Prayogo, MD · Faculty of Medicine Universitas Padjadjaran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06559488 on ClinicalTrials.gov